The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.

ABSTRACT: Gastric cancer is a biologically heterogeneous tumor. The identification of human epidermal growth factor receptor-2 (HER2) biomarker overexpression in gastric cancer represented a significant step towards unraveling the molecular complexity of this disease. Trastuzumab in combination with chemotherapy, in the first-line setting of patients with metastatic, HER2-positive gastric and gastroesophageal, represents the first targeted therapeutic to demonstrate improvement in response rate and survival in gastric cancer. However, not all patients with HER2-positive gastric cancer respond to trastuzumab and the majority of patients who do initially benefit from trastuzumab develop resistance to it. Advances in molecular oncology and cancer genomics have helped to classify gastric cancer into mol

SUBMITTER: Kelly CM 

PROVIDER: S-EPMC5056254 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature